Full Year 2023 Investor Presentation
26
Investor presentation
Full year 2023
Partnerships and acquisitions support future research and
development
Selected licenses
Selected acquisitions
2019
EpiDestiny
Novel treatment for
CVD/Rare disease
TA: Therapy area; CVD: Cardiovascular Disease; siRNA: Small interfering RNA
Note: Deal flow from 2019-2023Q4. Selection based on deal size
2020
2021
2022
2023
Emisphere
Oral formulations of
therapeutics
CORVIDIA
Novel treatments for
CVD/Rare disease
of prothena
Novel treatment for
CVD/Rare disease
Dicerna™
siRNA treatments
forma
THERAPEUTICS.
Novel treatments for
CVD/Rare disease
inversago
PHARMA
Novel treatments for
metabolic diseases
KBP
BIOSCIENCES
Treatment for
hypertension
Heartseed
Novel treatment for
CVD/Rare disease
Ventus
THERAPEUTICS
Novel treatment for
metabolic diseases
Valo
Novel treatment for
CVD/Rare disease
Novo NordiskⓇView entire presentation